Clinical Trial Update: Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating JM-010 and its components in Parkinson disease patients with dyskinesia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskinesia
• Parkinson Disease

Drugs mentioned

• JM-010

Snippet

Sponsor: Bukwang Pharmaceutical | Conditions: Dyskinesias, Parkinson Disease | Phase 2 | Status: TERMINATED